// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Improvements in pain, function and health status with subcutaneous tanezumab compared with placebo in patients with OA: pooled analysis of two randomized controlled trials

David Walsh - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy

Frances C Humby - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tocilizumab

Development and validation of a new tool to assess inflammatory foot disease activity in RA: the Rheumatoid Arthritis Foot Disease Activity Index

Anika Hoque - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA

David Walker - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Filgotinib

Combining clinical and ultrasound assessment to taper biologic therapies in patients with RA in routine clinical practice

Harikrishnan Pillai - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Lymphocyte DNA methylation mediates genetic risk at RA risk loci that are shared with other immune mediated diseases

Alexander D Clark - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Effect of rituximab on RA-associated bronchiectasis and comparison of 5-year respiratory survival with TNFi

Md Yuzaiful - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

Pregnancy vitamin D supplementation leads to greater offspring bone mineral density at 4 years: the MAVIDOS randomised placebo controlled trial

Elizabeth M Curtis - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

cholecalciferol

Maintaining musculoskeletal health: a randomised controlled trial of cognitive behaviour therapy among people at high risk of developing chronic widespread pain

Gary J Macfarlane - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Incidence, prevalence and associated comorbidity of axSpA within the UK: a retrospective database analysis

Christopher L. I Morgan - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Modelling longitudinal patient-reported outcome measures in JDM

Paris J Baptiste - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

National variation and factors associated with long-term opioid use for non-cancer pain in the first year of use

Meghna Jani - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epimorph

Secukinumab-related gastrointestinal safety in PsA and AS

Ioana A Onac - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Substance Abuse

Opioid withdrawal syndrome

secukinumab

Histological and molecular features of the diseased synovium in early untreated PsA in comparison with RA

Alessandra Nerviani - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Unrecognised inflammatory back pain: a retrospective review of people presenting to musculoskeletal physiotherapy with undiagnosed axSpA

: Carol McCrum - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Assessing the role of tendon T cell interactions in the development of chronicity in PsA

Emma Garcia-Melchor - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon Gamma

Ixekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes

Christopher J Edwards - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

Adalimumab

Concomitant treatment with MTX does not increase the efficacy of ustekinumab or TFNi in PsA: results from the PsABio study

Stefan Siebert - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Ustekinumab

Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis

Joanna Shim - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Non-serious infections in patients with RA: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Katie Bechman - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved